Name change serves to emphasise the corporate strength behind ABX in terms of global outreach, corporate culture and technological reliability, says Horiba
ABX Diagnostics, which has been part of the Horiba group since 1996, has been renamed Horiba ABX.
This name change, along with a similar change for all companies owned by the group, serves to emphasise the corporate strength behind ABX in terms of global outreach, corporate culture and technological reliability, says Horiba.
Complementing the new name is the launch of a dedicated UK website.
This profiles the new identity and includes a UK news and events section, which will be updated regularly, along with links to information on all the company's products and technologies in haematology and clinical chemistry analysis.
To follow later this year is a dedicated, protected, user area where customers will be able to keep abreast of local developments, receive important news, download information and communicate openly with registered peers as well as with Horiba ABX.
With a heritage dating back over 50 years, the Horiba group describes itself as a global leader in advanced analytical and measurement technology.
Instruments and systems manufactured globally by Horiba's 38 member companies set high quality and performance standards across a wide range of industry sectors.
Horiba companies manufacture over 1000 different products in four key industrial sectors: semiconductor research, production and quality control; scientific and environmental measurement; engine emission measurement and analysis; medical and diagnostic analysis.
Manufacturing 25% of the world's haematology analysers and now expanding into the clinical chemistry market with the ABX Pentra 400, Horiba ABX makes up over 80% of Horiba's medical division, which the group plans to expand considerably in the future.
Utilising Horiba's technical and production expertise in combination with Horiba ABX's R and D, manufacturing and expert market knowledge and understanding, Horiba ABX says it will be launching a number of new systems for small, mid and large sized hospitals and clinical diagnosis centres during the next five years.
Sector by sector this will include an extension of the haematology offering into larger laboratories, development of new technology for differentiating blood cells and ongoing enhancement and development of the chemistry and coagulation offering.
